Switch theme
Sign up to access all valuation multiples
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
2020
10K+
LTM Revenue $6.3B
LTM EBITDA $1.9B
$10.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Organon has a last 12-month revenue (LTM) of $6.3B and a last 12-month EBITDA of $1.9B.
In the most recent fiscal year, Organon achieved revenue of $6.4B and an EBITDA of $1.6B.
Organon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Organon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.3B | XXX | $6.4B | XXX | XXX | XXX |
| Gross Profit | $3.9B | XXX | $3.7B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $1.9B | XXX | $1.6B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $1.8B | XXX | $1.5B | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $1.0B | XXX | $864M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Organon's stock price is $9.
Organon has current market cap of $2.4B, and EV of $10.8B.
See Organon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.8B | $2.4B | XXX | XXX | XXX | XXX | $4.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Organon has market cap of $2.4B and EV of $10.8B.
Organon's trades at 1.7x EV/Revenue multiple, and 6.7x EV/EBITDA.
Equity research analysts estimate Organon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Organon has a P/E ratio of 2.3x.
See valuation multiples for Organon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $10.8B | XXX | $10.8B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 5.9x | XXX | 7.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 2.3x | XXX | 2.8x | XXX | XXX | XXX |
| EV/FCF | 16.4x | XXX | 18.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrganon's last 12 month revenue growth is -1%
Organon's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Organon's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organon's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Organon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Organon acquired XXX companies to date.
Last acquisition by Organon was XXXXXXXX, XXXXX XXXXX XXXXXX . Organon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Organon founded? | Organon was founded in 2020. |
| Where is Organon headquartered? | Organon is headquartered in United States of America. |
| How many employees does Organon have? | As of today, Organon has 10K+ employees. |
| Who is the CEO of Organon? | Organon's CEO is Mr. Kevin Ali. |
| Is Organon publicy listed? | Yes, Organon is a public company listed on NYS. |
| What is the stock symbol of Organon? | Organon trades under OGN ticker. |
| When did Organon go public? | Organon went public in 2021. |
| Who are competitors of Organon? | Similar companies to Organon include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Organon? | Organon's current market cap is $2.4B |
| What is the current revenue of Organon? | Organon's last 12 months revenue is $6.3B. |
| What is the current revenue growth of Organon? | Organon revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Organon? | Current revenue multiple of Organon is 1.7x. |
| Is Organon profitable? | Yes, Organon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organon? | Organon's last 12 months EBITDA is $1.9B. |
| What is Organon's EBITDA margin? | Organon's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Organon? | Current EBITDA multiple of Organon is 5.5x. |
| What is the current FCF of Organon? | Organon's last 12 months FCF is $658M. |
| What is Organon's FCF margin? | Organon's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Organon? | Current FCF multiple of Organon is 16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
